Version 2024

2024 ICD-10-CM Diagnosis Code C7A

Malignant neuroendocrine tumors

ICD-10-CM Code:
C7A
ICD-10 Code for:
Malignant neuroendocrine tumors
Is Billable?
Not Valid for Submission
Code Navigator:

Code Classification

  • Neoplasms
    (C00–D49)
    • Malignant neuroendocrine tumors
      (C7A)
      • Malignant neuroendocrine tumors
        (C7A)

C7A is a non-specific and non-billable diagnosis code code, consider using a code with a higher level of specificity for a diagnosis of malignant neuroendocrine tumors. The code is not specific and is NOT valid for the year 2024 for the submission of HIPAA-covered transactions. Category or Header define the heading of a category of codes that may be further subdivided by the use of 4th, 5th, 6th or 7th characters.

Specific Coding Applicable to Malignant neuroendocrine tumors

Non-specific codes like C7A require more digits to indicate the appropriate level of specificity. Consider using any of the following ICD-10-CM codes with a higher level of specificity when coding for malignant neuroendocrine tumors:

  • C7A.0 for Malignant carcinoid tumors - NON-BILLABLE CODE

  • Use C7A.00 for Malignant carcinoid tumor of unspecified site - BILLABLE CODE

  • C7A.01 for Malignant carcinoid tumors of the small intestine - NON-BILLABLE CODE

  • C7A.02 for Malignant carcinoid tumors of the appendix, large intestine, and rectum - NON-BILLABLE CODE

  • C7A.09 for Malignant carcinoid tumors of other sites - NON-BILLABLE CODE

  • Use C7A.1 for Malignant poorly differentiated neuroendocrine tumors - BILLABLE CODE

  • Use C7A.8 for Other malignant neuroendocrine tumors - BILLABLE CODE

Tabular List of Diseases and Injuries

The following annotation back-references are applicable to this diagnosis code. The Tabular List of Diseases and Injuries is a list of ICD-10-CM codes, organized "head to toe" into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more.


Code Also

Code Also
A "code also" note instructs that two codes may be required to fully describe a condition, but this note does not provide sequencing direction.
  • any associated multiple endocrine neoplasia MEN syndromes E31.2

Use Additional Code

Use Additional Code
The “use additional code” indicates that a secondary code could be used to further specify the patient’s condition. This note is not mandatory and is only used if enough information is available to assign an additional code.
  • code to identify any associated endocrine syndrome, such as:
  • carcinoid syndrome E34.0

Type 2 Excludes

Type 2 Excludes
A type 2 excludes note represents "Not included here". An excludes2 note indicates that the condition excluded is not part of the condition represented by the code, but a patient may have both conditions at the same time. When an Excludes2 note appears under a code, it is acceptable to use both the code and the excluded code together, when appropriate.
  • malignant pancreatic islet cell tumors C25.4
  • Merkel cell carcinoma C4A

Patient Education


Cancer

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.

Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, immunotherapy or other types of biologic therapy, or stem cell transplantation.

NIH: National Cancer Institute


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.